Zantac litigation

9 October 2024 - Statement: Zantac (ranitidine) litigation – settlement agreements reached

GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion.

18 September 2024 - Statement: Zantac (ranitidine) litigation – Russell and Hughes cases

GSK plc (LSE/NYSE: GSK) today confirmed it has reached two confidential settlements in cases filed in California State Court with Mr. John Russell and Annette Hughes.

11 September 2024 - Statement: Zantac (ranitidine) litigation – Dixon case

GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court. GSK does not admit any liability in this settlement. The case will now be dismissed.

27 August 2024 - Statement: Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision

GSK plc (LSE/NYSE: GSK) welcomes today’s decision by the Delaware Supreme Court that it will review the Delaware Superior Court’s decision allowing the introduction of plaintiffs’ expert evidence at trial. Interlocutory reviews are granted in exceptional circumstances, and GSK is pleased that the Supreme Court is of the view that such circumstances are present here.

15 August 2024 - Statement: Zantac (ranitidine) litigation - Florida State Court Daubert Ruling in Wilson case

Florida State Court’s ruling finds in favour of GSK and other defendants, excluding plaintiff’s experts’ general and specific causation testimony that ranitidine was a significant risk factor for Wilson’s prostate cancer

05 August 2024 - Statement: Zantac (ranitidine) litigation - Joiner case

Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff's colorectal cancer

29 July 2024 - Statement: Zantac (ranitidine) litigation - Kimbrow case

GSK has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court.

28 June 2024 -​Statement: Zantac (ranitidine) litigation – Gross case

GSK has reached a confidential settlement with Martin Gross resolving the case he filed.

10 June 2024 - Statement: Zantac (ranitidine) litigation - GSK starts process for appeal of recent Delaware Daubert decision

GSK confirms that the company has taken the first step to seek appeal of the recent Daubert ruling by the Delaware Superior Court.

10 June 2024 - Statement: Zantac (ranitidine) litigation - Kasza case

GSK welcomes the plaintiff's voluntary dismissal of the Kasza case previously pending in Illinois state court.

1 June 2024 - Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling

GSK disagrees with ruling by the Delaware State Court and will immediately seek an appeal.

23 May 2024 - Statement: Zantac (ranitidine) litigation - Valadez and Williams cases

Jury in Valadez case in Illinois state court finds GSK and Boehringer Ingelheim not liable for plaintiff's colorectal cancer. Separately, the company welcomed the court ruling dismissing the Williams case that was due to start on 23 May 2024.

29 February 2024 - Statement: Zantac (ranitidine) litigation

GSK confirmed it has reached a confidential settlement with Boyd/Steenvoord.

1 February 2024 - Statement: Zantac (ranitidine) litigation

GSK today confirmed it has reached a confidential settlement with David Browne, resolving the case filed by Mr. Browne in California state court.

11 October 2023 - Statement: Zantac (ranitidine) litigation

GSK today confirmed it has reached a confidential settlement in the Cantlay/Harper case filed in California state court.

23 June 2023 - Statement: Zantac (ranitidine) litigation

GSK confirmed it had reached a confidential settlement with James Goetz, dismissing the case in California state court.

12 May 2023 - Statement: Zantac (ranitidine) litigation

GSK welcomes the decision of the British Columbia Supreme Court in Dussiaume v. Sandoz Canada Inc. 2023 BCSC 795 dismissing a proposed class action on behalf of a class of ranitidine users in Canada.

24 March 2023 - Statement: Zantac (ranitidine) litigation

GSK issued a statement in response to the Sargon ruling by the California state court in the Goetz case.

7 December 2022 - Statement: Zantac (ranitidine) litigation

The MDL Court dismissed all cases alleging the five remaining cancers in the MDL.

16 August 2022 - Statement: Zantac (ranitidine) litigation

Notice of plaintiff's voluntary dismissal in the Bayer case in Madison county, Illinois.

11 August 2022 - Statement Zantac (ranitidine) litigation

Response to speculative commentary regarding U.S. Zantac litigation.